Literature DB >> 25273645

Impact of haemophilia with inhibitors on caregiver burden in the United States.

M DeKoven1, S Karkare, W C Lee, L A Kelley, D L Cooper, H Pham, J Powers, T Wisniewski.   

Abstract

Inhibitor development complicates haemophilia treatment and may impact caregiver burden. Compare overall burden of caregivers of children with/without inhibitors in the United States using a novel disease-specific questionnaire and the previously validated CarerQol. An on-line questionnaire with six burden domains (i.e. emotional stress, personal sacrifice, financial burden, medical management, child's pain, and transportation) and three visual analogue scales (VAS) was developed based upon a targeted literature review and previous survey findings. The study sample consisted of caregivers of children with haemophilia. The total burden score was calculated by summing the six individual burden domain scores. Higher scores represented greater burden. Descriptive statistics was performed to examine the sample characteristics. The Wilcoxon rank-sum test was performed to compare burden by inhibitor status. All variables were considered significant at P < 0.001. A total of 310 caregivers completed the survey; 30 of them reported caring for a child with an inhibitor. A majority of caregivers of children with inhibitors were mothers (80.0%) and between 35 and 44 years of age (56.7%). Caregivers of children with inhibitors reported significantly higher median total burden scores (99.0 vs. 76.5, P < 0.0001) and median burden-VAS scores (5.5 vs. 3.0, P < 0.0001), as compared to those caring for children without inhibitors. A similar trend was seen across all the six burden domains, with greatest difference in the median burden scores observed in the 'personal sacrifice' (3.2 vs. 2.0) and 'transportation' (3.3 vs. 2.3) domains. Burden of caregivers should be considered when assessing the psychosocial aspects of managing patients with inhibitors.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  burden; caregiver; haemophilia; inhibitors; quality of life

Mesh:

Substances:

Year:  2014        PMID: 25273645     DOI: 10.1111/hae.12501

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

Review 1.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 2.  The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries.

Authors:  Fadi Nossair; Courtney D Thornburg
Journal:  Ther Adv Hematol       Date:  2018-07-02

3.  Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention.

Authors:  Maureen E Lyon; Jessica D Thompkins; Karen Fratantoni; Jamie L Fraser; Sandra E Schellinger; Linda Briggs; Sarah Friebert; Samar Aoun; Yao Iris Cheng; Jichuan Wang
Journal:  BMJ Support Palliat Care       Date:  2019-07-25       Impact factor: 4.633

4.  AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.

Authors:  Tadashi Matsushita; Nobuaki Suzuki; Azusa Nagao; Chiai Nagae; Haruko Yamaguchi-Suita; Yui Kyogoku; Akiko Ioka; Keiji Nogami
Journal:  BMJ Open       Date:  2022-03-14       Impact factor: 2.692

5.  Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

Authors:  Karissa Johnston; Jayson M Stoffman; Alexis T Mickle; Robert J Klaassen; Demitri Diles; Shade Olatunde; Lina Eliasson; Roxana Bahar
Journal:  Patient Prefer Adherence       Date:  2021-06-24       Impact factor: 2.711

6.  The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.

Authors:  Carolyn E Schwartz; Victoria E Powell; Jun Su; Jie Zhang; Adi Eldar-Lissai
Journal:  Qual Life Res       Date:  2018-02-01       Impact factor: 4.147

7.  The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me.

Authors:  Simon Fletcher; Kathryn Jenner; Michael Holland; Kate Khair
Journal:  Health Expect       Date:  2021-12-08       Impact factor: 3.377

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.